Zenosense
Avda Cortes Valencianas 58
Planta 5
Valencia
46015
Tel: 34-96-045-4202
Website: https://www.zenosense.com/
Email: info@zenosense.net
About Zenosense
Zenosense Inc. 's primary focus, through our joint venture ownership in MIDS Medical Ltd., is the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiacâ„¢, and is also the holder of an exclusive global license agreement to develop and market effective medical devices for use in hospitals and primary healthcare settings targeting the early detection of both deadly bacteria and certain cancers in the exhaled breath of patients.YEAR FOUNDED:
2008
FOLLOW ZENOSENSE:
Tweets by Zenosense
9 articles about Zenosense
-
Zenosense: MIDS Hybrid Strip - Successful Initial Test Results
11/16/2017
The MIDS Hybrid Strip system replicates, as closely as possible, a fully integrated Lab on Chip MIDS test strip set-up.
-
Zenosense Release: MIDS Hybrid Strip Detection Testing To Commence
7/5/2017
-
Zenosense: MIDS Medical Engages Future Diagnostics For Assay Consulting Services
3/29/2017
-
Zenosense: MIDS Quantitative Testing Results
3/13/2017
-
Zenosense: MIDS Quantitative Testing Commences
2/22/2017
-
Zenosense: Is Something Big On The Cards?
2/20/2017
-
Zenosense Release: New Patent Application For Additional MIDS Detection Method
1/23/2017
-
Zenosense MIDS Cardiac Bench Reader Development
11/1/2016
-
Zenosense General Update - Cardiac Device Development
9/20/2016